{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:11:16Z","timestamp":1780452676509,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204221"],"award-info":[{"award-number":["82204221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016109","name":"Taishan Industry Leading Talents","doi-asserted-by":"publisher","award":["tscx202312146"],"award-info":[{"award-number":["tscx202312146"]}],"id":[{"id":"10.13039\/501100016109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118361","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:02:14Z","timestamp":1763636534000},"page":"118361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P3","title":["Structure-guided rational design of dual-target CGRP antagonist\/5HT1F agonist therapeutics for migraine"],"prefix":"10.1016","volume":"302","author":[{"given":"Fangxia","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejmech.2025.118361_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071429","article-title":"CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine","volume":"10","author":"Capi","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118361_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine--current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118361_bib3","first-page":"7906","volume":"63","author":"Bucknell","year":"2020"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118361_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s11739-016-1489-4","article-title":"Anti-CGRP monoclonal antibodies in migraine: current perspectives","volume":"11","author":"Giamberardino","year":"2016","journal-title":"Intern. Emerg. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118361_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2025.118361_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"de Vries","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118361_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.90.2.408","article-title":"Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase","volume":"90","author":"Adham","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118361_bib8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF00167231","article-title":"Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways","volume":"348","author":"Adham","year":"1993","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"4\u20135","key":"10.1016\/j.ejmech.2025.118361_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0028-3908(97)00020-8","article-title":"Cloning and characterization of the Guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog","volume":"36","author":"Adham","year":"1997","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118361_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41582-023-00842-x","article-title":"The 5-HT(1F) receptor as the target of ditans in migraine - from bench to bedside","volume":"19","author":"Mitsikostas","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"4 Suppl 1","key":"10.1016\/j.ejmech.2025.118361_bib11","first-page":"163","article-title":"Lasmiditan for the treatment of migraines with or without aura in adults","volume":"50","author":"Berger","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ejmech.2025.118361_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/NDT.S25531","article-title":"Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan","volume":"10","author":"Rizzoli","year":"2014","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118361_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J. Headache Pain"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118361_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","article-title":"5-HT1F receptor agonists in acute migraine treatment: a hypothesis","volume":"23","author":"Ramadan","year":"2003","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118361_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pharmthera.2012.08.011","article-title":"Basic mechanisms of migraine and its acute treatment","volume":"136","author":"Edvinsson","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118361_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118361_bib17","first-page":"711","article-title":"Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine","volume":"10","author":"Tepper","year":"2009","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118361_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118361_bib19","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1021\/jm500364u","article-title":"Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine","volume":"57","author":"Bell","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118361_bib20","first-page":"447","article-title":"Bacterial vaginosis: its importance in obstetrics","volume":"59","author":"Woodrow","year":"1998","journal-title":"Hosp. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118361_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118361_bib22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.str.2010.05.014","article-title":"Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism","volume":"18","author":"ter Haar","year":"2010","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118361_bib23","article-title":"A comprehensive review of Zavegepant as abortive treatment for migraine","volume":"10","author":"Noor","year":"2022","journal-title":"Health Psychol. Res."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118361_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"Croop","year":"2022","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118361_bib25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1124\/jpet.113.206458","article-title":"In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232","volume":"347","author":"Hostetler","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118361_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41422-021-00527-4","article-title":"Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT(1F)-G protein complex","volume":"31","author":"Huang","year":"2021","journal-title":"Cell Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:00:13Z","timestamp":1773331213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0223523425011262"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118361","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided rational design of dual-target CGRP antagonist\/5HT1F agonist therapeutics for migraine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118361"}}